Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has announced the start of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its drug candidate ONC010. This step is a critical component of the company's chemistry, manufacturing and controls (CMC) strategy as it moves toward investigational new drug (IND)-enabling studies and planning for first-in-human clinical evaluation.
The program will focus on optimizing synthetic processes, improving yield and reproducibility, and scaling production of key intermediates required for downstream manufacturing and formulation. The work is being conducted in collaboration with Dalton Pharma Services, aiming to establish a robust, scalable manufacturing process that can support continued preclinical development, regulatory readiness, and future clinical supply requirements.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumors.
For more information about Onco-Innovations, visit https://oncoinnovations.com/.
The full press release is available at https://nnw.fm/kfFWv.
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. NetworkNewsWire (NNW) is a specialized communications platform with a focus on financial news and content distribution. For more information, visit https://www.NetworkNewsWire.com.
